Pancreatic cancer is a highly malignant tumor with an extremely low five-year survival rate, especially for patients with locally advanced pancreatic cancer (LAPC), who have limited treatment options and poor prognosis. LAPC is defined based on the degree of tumor contact with adjacent blood vessels and is often considered “unresectable” at diagnos...

Colorectal Cancer (CRC) is the third most common malignant tumor worldwide, and its prognosis assessment primarily relies on the TNM staging system. However, the current TNM staging system does not fully account for the presence and count of Tumor Deposits (TDs) in lymph node-positive colorectal cancer. Tumor deposits refer to discrete tumor nodule...

Targeted Delivery of Napabucasin with Radiotherapy in Diffuse Midline Glioma Background Introduction Diffuse Midline Glioma (DMG) is the most aggressive primary brain tumor in children, with a median survival typically less than one year. Although radiation therapy (RT) is the current standard treatment, it only provides transient symptom relief an...

ctDNA Trajectories Predict Survival in Trifluridine/Tipiracil-Treated Metastatic Colorectal Cancer Patients Academic Background Metastatic colorectal cancer (mCRC) is one of the leading causes of cancer-related deaths worldwide. Despite recent advancements in diagnosis and treatment, the prognosis for advanced-stage patients remains poor. Triflurid...

Academic Background Acute Myeloid Leukemia (AML) is a malignant blood disorder, with the core of its treatment being induction chemotherapy, typically involving a combination of cytarabine and anthracyclines (such as daunorubicin). Although this treatment regimen has been in use since the 1980s, questions regarding the optimal dose of daunorubicin ...